Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28295855 | 0.88 | PPARA (0.49) | KMT2APTGS2DPP4PTGER3PTGER1 | |
| SCHEMBL429540 | 0.87 | DPP4 (0.58) | KMT2ADPP4PTGER3PTGER1PTGER4 | |
| SCHEMBL27840283 | 0.87 | DPP4 (0.58) | KMT2ADPP4PTGER3PTGER1PTGER4 | |
| SCHEMBL28293956 | 0.83 | PPARA (0.52) | — | |
| SCHEMBL8604437 | 0.83 | PTGS2 (0.61) | PTGS2 | |
| SCHEMBL10609360 | 0.81 | DPP4 (0.50) | KMT2ADPP4PTGER3PTGER1PTGER4 | |
| SCHEMBL27615436 | 0.80 | PTGS2 (0.65) | KMT2APTGS2HDAC2HDAC6CA12 | |
| SCHEMBL5584302 | 0.80 | TAAR1 (0.52) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6075489 | 0.78 | TAAR1 (0.48) | KMT2ACA12CA1CA2CA7 | |
| Sulfuric Acid SCHEMBL9303438 | 0.77 | PPARA (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | SLC6A2 1499/4885SLC6A4 965/4885SLC6A3 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.